Charles C. Wykoff, MD, PhD

Suprachoroidal corticosteroid shows visual, anatomic improvements in DME eyesSuprachoroidal triamcinolone acetonide (CLS-TA, Clearside Biomedical) injection resulted in visual and anatomic improvements in eyes with diabetic macular edema, particularly in those that were treatment-naïve. Multiple injections of the investigational treatment were well-tolerated and associated with a low incidence of IOP elevation.
Tracking growth of ultra-widefield imaging in disease managementUltra-widefield imaging has become an important component of a thorough eye exam and is taking on a larger role in retina and comprehensive ophthalmology.
TREX-AMD trial finds visual gains from treat-and-extend vs. monthlyTreat-and-extend approach for neovascular AMD leads to beneficial results in 2-year clinical trial.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progressionTreatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
Aflibercept performance consistent in DME regardless of prior anti-VEGF therapyOutcomes from a study of intravitreal aflibercept were evaluated for patients with and without prior anti-vascular endothelial growth factor therapy for diabetic macular edema.